Moderately Heavy Atom-Substituted BODIPY Photosensitizer with Mitochondrial Targeting Ability for Imaging-Guided Photodynamic Therapy.

Advanced photodynamic therapy requires photosensitizers with targeting, diagnostic, and therapeutic properties. To fulfill this multifunctionality, we report the synthesis of two triphenylphosphonium (TPP)-functionalized boron-dipyrromethene (BODIPY) dyes, TPPB-H and TPPB-Br, which incorporate a hydrogen atom and dibrominated vinyl moiety at the 6-position of the BODIPY core, respectively. The heavy-atom effect of the moderately heavy bromine atoms allowed TPPB-Br to achieve a proper balance between the toxic singlet oxygen (O) production and fluorescence efficiencies.

Caries experience among adults in core Sámi areas of Northern Norway.

Objectives: Dental caries is a major oral health problem among indigenous people worldwide, but knowledge on this issue among the indigenous Sámi people in Norway is scarce. The aim of the study was to describe dental caries experience in an adult population in core Sámi areas of Northern Norway and to assess the corresponding associations with socio-demographic, socioeconomic and oral health-related behavioural factors.

Methods: This cross-sectional study is based on data from the Dental Health in the North study (2033 participants aged 18-75 years).

Periodontal health in an indigenous Sámi population in Northern Norway: a cross-sectional study.

Background: The aim of the study was to describe prevalence, severity and distribution of periodontal disease as well as associated risk factors in an indigenous Sámi population in Northern Norway, and to investigate differences between the indigenous Sámi and the non-Sámi population.

Methods: This cross-sectional study included data from the Dental Health in the North study (N = 2078; 18-75 years). Data on Ethnicity, household income, education, smoking habits, dental attendance, and tooth brushing habits were collected by a questionnaire.

Early P2Y12 Inhibitors Escalation in Primary PCI Patients: Insights from the RENOVAMI Registry.

Background: Early escalation from clopidogrel to new generation P2Y12 inhibitors is common practice in patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI). Real-world data about this strategy, however, are limited.

Methods: From 2012 to 2015, 1,057 consecutive STEMI patients treated with pPCI in an Italian hub-and-spoke network were prospectively included in an observational registry (RENOVAMI, ClinicalTrials.